Vaccines

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

Cody Stubblefield, RN, gives the first of two injections of an antibody combination to Caroline Davis to protect her from COVID-19.

Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization

Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.

Children’s Hospital doctors and nurses brought flu vaccines to underserved areas in Nashville through its “Mobile Flu Fighter!” project.

Children’s Hospital program brought flu vaccines to underserved areas

Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines

Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.

Omicron evades some but not all monoclonal antibodies: study

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Grant boosts vaccine effectiveness research

1 2 3 4 5 6 14